SCHEMBL21708004

SCHEMBL21708004

Cc1ccc2nc(-c3cccc(F)c3)cn2c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 10/20 0.65
RAB9A P51151 9/20 0.65
KDM4E B2RXH2 7/20 0.65
ALDH1A1 P00352 6/20 0.65
SMN1; SMN2 Q16637 5/20 0.65
PKM P14618 4/20 0.65
HPGD P15428 4/20 0.65
KMT2A Q03164 3/20 0.65
TP53 P04637 3/20 0.65
HSD17B10 Q99714 3/20 0.65
TSHR P16473 2/20 0.65
CDK5 Q00535 1/20 0.65
CDK5R1 Q15078 1/20 0.65
MEN1 O00255 2/20 0.61
PAX8 Q06710 2/20 0.61
MITF O75030 1/20 0.61
KDM5A P29375 1/20 0.61
KDM5C P41229 1/20 0.61
MAPT P10636 4/20 0.59
LMNA P02545 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26603218 0.84 APP (0.52) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL31683141 0.84 APP (0.52) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL21708003 0.82 NPC1 (0.65) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL21708017 0.82 NPC1 (0.65) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL1691890 0.81 ALDH1A3 (0.82) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL1987470 0.80 NPC1 (0.96) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL26689119 0.80 NPC1 (0.72) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL6390907 0.80 RAB9A (0.69) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL1691197 0.79 ALDH1A3 (0.70) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL8100231 0.79 GRIN1 (0.49) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US claimed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP claimed
WO-2023203163-A1 COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS UNIVERSITE PARIS CITE (FR) 2023-10-26 WO disclosed
EP-4265248-A1 COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS Université Paris Cité (FR) 2023-10-25 EP disclosed
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US disclosed
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US disclosed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP disclosed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine DOT1L, NSD1, KDM3A NPC1 4209/4885RAB9A 3350/4885KDM4E 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.